非核苷类逆转录酶抑制剂奈韦拉平

摘要/Abstract

摘要： 艾滋病是严重威胁人类健康的传染性疾病,它是由HIV 引发,特别是HIV-1 。奈韦拉平是一种新型的非核苷类逆转录酶抑制剂,该药与核苷类逆转录酶抑制剂或蛋白酶抑制剂合用可用于治疗艾滋病,单独用药可用于预防HIV 感染和母婴传播。

关键词: 药理学, 综述, 奈韦拉平, 非核苷类逆转录酶抑制剂, 艾滋病, 药物治疗

Abstract: Acquired immune deficiency syndrome(AIDS),a great epidemic threatening disease,is caused by the human immunodeficiency virus(HIV),particularly the strain known as HIV-1.Nevirapine,a novel nonnucleoside reverse transcriptase(RT)inhibitor combined with nucleoside analogue RT inhibitors orProtease inhibitors,can be used in treatment ofPatients with HIV infection.AS an agent used alone,nevirapine canPrevent vertical transmission or HIV infection.

Key words: pharmacology, nevirapine, non-nucleoside reverse transcriptase inhibitor, AIDS, pharmacotherapy

中图分类号:

涂国刚, 李少华. 非核苷类逆转录酶抑制剂奈韦拉平[J]. 中国临床药理学与治疗学, 2003, 8(6): 604-607.

TU Guo-Gang, LI Shao-Hua. Nevirapine, a non-nucleoside reverse transcriptase inhibitor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 604-607.

参考文献

1 Hargrave KD,Proudfoot JR,Adams J,et al.5.11-Dihydro-6H-dipyrido(3,2-B:2',3'-E)1994.12
2 Temesgen Z,Wright AJ.Antiretrovirals[J].Mayo ClinProc,1999;74:1284-301
3 Voelker R.New HIV drugs cast in supporting roles[J].JAMA,1996;276:585-6
4 GuaylA,MusokeP,Fleming T,et al.Intrapartum and neonatal single-dose nevirapine compared with zidovndine forPrevention of mother-to-child transmission of HIV-1 in Kampala,Uganda:HIVNET 012 randomised trial[J].Lancet,1999;354:795-802
5 Marseille E,Kohn JG,Mmiro F,et al.Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa[J].Lancet,1999;354:803-9
6 Schneider H,Christmann A.Process forPreparing nevirapine[S].US.Cl.540 495.5569760.1996.10
7 KohlstaedtlA,Wang J,Friedman JM,et al.Crystal structure at 3.5? resolution of HIV-1 reverse transicriptase complexed with an inhibitor[J].Science,1992;256:1783-90
8 Wu JC,Warren TC,Adams J,et al.A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site [J].Biochemistry,1991;30:2022-6
9Palladino DEH,Hopkins JL,Ingraham RH,et al.High-performanceliquid chromatography andPhotoaffinity crosslinking to explore the binding environment of nevirapine to reverse transeriptase of human immunodeficiency virs type-1[J].J Chromatogr A,1994;676:99-112
10 Hannongbua S,Prasithichokekul S,PungpoP.Conformational analysis of nevirapine,a non-nucleoside HIV-1 reverse transcriptase inhibitor,based on quantum mechanical calculations[J].J Comput AlidedMol Des,2002;15:997-1004
11 Spence RA,Kati WM,Anderson KS,et al.Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors[J].Science,1995;267:988-93
12 SmithPF,DiCenzo R,Morse GD.ClinicalPharmacokinetics of non-nucleoside reverse transcriptase inhibitors [J].ClinPharmacokinet,2001;40:893-905
13 KouPRA,Merluzzi VJ,Hargrave KD,et al.Inhibition of human immunodeficiency virus type-1(HIV-1)replication by the dipyridodiazepinone BI-RG-587[J].J Infect Dis,1991;163:966-70
14 Merluzzi VJ,Hargrave KD,Labadia M,et al.Inhibition of HIV-1 replication by a nonucleoside reverse transcriptase inhibitor[J].Science,1990;250:1411-3
15 Erickson DA,Mather G,Trager WF,et al.Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromesP-450[J].Drug Metab Dispos,1999;27:1488-95
16 RiskaPS,Joseph DP,Dinallo RM,et al.Biotransformation of nevirapine,! a non-nucleoside HIV-1 reverse transcriptase inhibitor,in mice,rabs,rabbits,dogs,monkeys,and chimpanzees[J].Drug Metab Dispos,1999;27:1434-47
17 RikaP,Lamson M,Mac Gregor T,et al.Disposition and biotransformation of the antiretroviral drug nevirapine in human[J].Drug Metab Dispos,1999;27:895-901
18 Holtzer CD,Coleman RL.Use of nonnucleoside reverse transcriptase inhibitors[J].Am J Health SystPhorm,1998;53:283-7
19 Montaner JS,ReissP,Cooper D,et al.A randomized doubleblind trial comparing combinations of nevirapine,didanosine,and zidovadine for HIV-infectedPatients:the INCAS trial;Italy,the netherlands.Canada and australia study[J].JAMA,1998;297:930-7
20 RobinsonP,Montaner J.Long-term follow-uPofPatients treated with nevirapine(NVP)based combination therapy within the INCAS trial [J].Int Conf AIDS,1998;12:87
21 Chen F,Pau AR,Piscitelli SC.Update onPrevention vertical transmission of HIV type 1[J].Am J Health SystPharm,2000;57:1616-23
22 Taylor GP,Lyall EGH,Back D,et al.Pharmacological implications oflengthened in vitro exposure to nevirapine[J].Lancet,2000;355:2134-5
23 D' Aqulia RT,Hughes MD,Johnson VA,et al.Nevirapine,zidovudine and didanosine compared with zidovudine and didanosine inPatients with HIV-1 infection:a randomized,double-blind,placebocotrolled trial[J].Ann Intern Med,1997;124:1019-30
24 Cattelan AM,Trevenzoli M,Sassetl,et al.Toxic epidermal necrolysis induced by nevirapine therapy:descriPof two case and review of theliterature[J].J Infect,2001;43:246-9
25 Johnson S,Chan J,Bennett CL.Hepatotoxicity afterProphylaxis with a nevirapine-containing antiretroviral regimen[J].Ann InternMed,2002;137:146-7
26 Richman DD,Havlir D,Corbeil J,et al.Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy[J].J Virol,1994;68:1660-6
27 Richman D,Shih CK,Lowry J,et al.Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture[J].Proc Natl Acad Sci USA,1991;88:11241-5
28 Zhu QY,Scarborough A,Polsky B,et al.Drug combinations and effectParameters of zidovudine,stavudine and nevirapine in standardized drug-sensitive and resistant HIV type 1 stranis[J].AIDS Res Hun Retroviruses,1996;12:507-17
29 KouPRA,Brester R,Grob R,et al.Nevirapine synergistically inhibitors HIV-1 replication in combination with zidovudine,interferon and CD4 immunoadhesion[J].AIDS,1993;7:1181-4

[1]	游蓉丽, 黄玉荣, 毛睿, 海丽娜, 王颖莉, 王艳. 基于血清代谢组学与网络药理学探究复方苦参注射液治疗肺癌的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(9): 988-999.
[2]	胡康一, 曹林忠, 万超超, 尚征亚, 杨小瑞, 张勇杰. 基于线粒体功能障碍探讨中药防治激素性股骨头坏死的基础研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 688-696.
[3]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[4]	曹放, 覃开蓉, 郑国爽, 赵德伟. 基于网络药理学探讨银杏叶干预激素性股骨头坏死的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(3): 266-275.
[5]	马广立, 张菁. 定量药理学在疫苗研发中应用的概述与展望[J]. 中国临床药理学与治疗学, 2023, 28(3): 315-322.
[6]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[7]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[8]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[9]	陈玉林, 蒋虎刚, 王新强, 刘凯, 李应东, 安涛, 赵信科. 基于网络药理学和分子对接探讨芪参益心颗粒治疗射血分数保留型心力衰竭的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(10): 1081-1092.
[10]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[11]	刘艳之, 王艳, 刘凯丽, 周文华, 朱平, 王颖莉, 杜守颖. 西黄丸对H22荷瘤小鼠的抑瘤作用及其机制研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 754-761.
[12]	姚倩, 陈赟, 商娟, 袭晓昀, 陈影, 顾潇, 居文政, 邹建东, 卢苏, 许美娟. 基于HPLC-Q-TOF/MS和网络药理学的清心滋肾方防治绝经综合征潜在药效物质基础和作用机制研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 481-497.
[13]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[14]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[15]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.